Kymera Therapeutics, Inc.
KYMR
株式のランク
#2248
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
株価
$108.61
最終同期: 2026-10-19
時価総額
$8.93B
変化（1日）
3.65%
変化（1年）
79.51%
国
US
取引 Kymera Therapeutics, Inc. (KYMR)
カテゴリー
Healthcare
Kymera Therapeutics, Inc.（KYMR）のEPS
June 2026 時点のEPS TTM: $-3.25
Kymera Therapeutics, Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-3.25です。2023年末には、EPSは$-2.52で、2022年のEPS$-2.87と減少でした。
Kymera Therapeutics, Inc.のEPS履歴（2018から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-3.25 | 9.06% |
| 2024 | $-2.98 | 18.25% |
| 2023 | $-2.52 | -12.20% |
| 2022 | $-2.87 | 37.32% |
| 2021 | $-2.09 | 111.11% |
| 2020 | $-0.99 | 6.45% |
| 2019 | $-0.93 | 93.75% |
| 2018 | $-0.48 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -632.92% |
US
|
|
| $-7.98 | 145.54% |
US
|
|
| $-5.29 | 62.77% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -953.54% |
NL
|
